Sign In
Buy KTRA
$0.215
+0 (+0%)
At Close: Jan 16, 2025
STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Announces an Investigation of Kintara Biopharma, Inc. - KTRA
08:15pm, Tuesday, 09'th Apr 2024
NEW YORK , April 9, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securit
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Kintara Th
Kintara (KTRA) Stock Soars on Merger Agreement With TuHURA
11:41am, Thursday, 04'th Apr 2024
Kintara (KTRA) inks a definitive merger agreement with TuHURA for an all-stock transaction. It is expected to close in the third quarter of 2024.
Shareholder Alert: Ademi LLP investigates whether Kintara Therapeutics, Inc. has obtained a Fair Price in its transaction with TuHURA
01:43pm, Wednesday, 03'rd Apr 2024
MILWAUKEE , April 3, 2024 /PRNewswire/ -- Ademi LLP is investigating Kintara (Nasdaq: KTRA) for possible breaches of fiduciary duty and other violations of law in its transaction with TuHURA. Click
Why Is Kintara Therapeutics (KTRA) Stock Up 103% Today?
09:46am, Wednesday, 03'rd Apr 2024
Kintara Therapeutics (NASDAQ: KTRA ) stock is rocketing higher on Wednesday after the biopharmaceutical company announced plans to merge with TuHURA Biosciences . Kintara Therapeutics and TuHURA Biosc
KTRA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Kintara Therapeutics, Inc. Is Fair to Shareholders
09:28am, Wednesday, 03'rd Apr 2024
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Kintara Therapeutics, Inc. (NASDAQ: KTRA) and TuHURA Biosciences, Inc. is fair to Kinta
Kintara Therapeutics and TuHURA Biosciences Enter into Definitive Merger Agreement
07:00am, Wednesday, 03'rd Apr 2024
TuHURA is planning to advance a single Phase 3 trial for IFx-2.0 personalized cancer vaccine as adjunctive therapy with Keytruda® in first-line therapy for advanced Merkel cell carcinoma in 2H 2024 u
Sizing Your Penny Stocks Position, 3 Tips
06:26am, Sunday, 31'st Mar 2024
Sizing positions correctly is a cornerstone of successful investing, especially when dealing with penny stocks. The unique nature of penny stocks, with their potential for substantial gains, requires
Kintara Therapeutics Announces Expansion of REM-001 Clinical Study to Include Patients on Pembrolizumab
09:00am, Wednesday, 27'th Mar 2024
SAN DIEGO, March 27, 2024 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer thera
Kintara Therapeutics Announces Fiscal 2024 Second Quarter Financial Results and Provides Corporate Update
04:07pm, Wednesday, 14'th Feb 2024
SAN DIEGO , Feb. 14, 2024 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer ther
Kintara Therapeutics Announces Initiation of REM-001 Clinical Trial for the Treatment of Cutaneous Metastatic Breast Cancer
09:00am, Monday, 12'th Feb 2024
- 15-patient Open Label Study to Confirm Planned Dose and Optimized Study Design Leading to a Phase 3 Clinical Trial in CMBC Patients - SAN DIEGO , Feb. 12, 2024 /PRNewswire/ -- Kintara Therapeutics,
Kintara Therapeutics Announces Review of Strategic Alternatives
09:00am, Thursday, 07'th Dec 2023
- Ladenburg Thalmann Hired as Financial advisor - SAN DIEGO , Dec. 7, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused
Kintara Therapeutics Granted Extension by Nasdaq to Regain Compliance with the Stockholders' Equity Continued Listing Requirement
09:00am, Tuesday, 05'th Dec 2023
SAN DIEGO , Dec. 5, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therap
Top 5 Health Care Stocks That Could Blast Off In December - DBV Technologies (NASDAQ:DBVT), Cigna Group (NYSE:CI)
10:47am, Friday, 01'st Dec 2023
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Kintara Therapeutics Announces Fiscal 2024 First Quarter Financial Results and Provides Corporate Update
04:10pm, Monday, 13'th Nov 2023
SAN DIEGO , Nov. 13, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer thera
